Abstract:
Background: Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative, monoclonal, indolent hemopathy characterized by pathologically
increased synthesis of mature but immunologically dysfunctional B lymphocytes. CLL is considered the pathology of the adult with comorbidities, whose
average age is 55 years, who is integrated into the work field. Despite advances in the field of medicine, CLL remains an incurable disease, but the use of
targeted, personalized therapy with new agents’ conditions not only increases the life span, but also improves the of quality life of these patients, ensuring
social, family and professional integration. This fact presents a favourable socioeconomic impact, a valuable indicator especially in countries with a low
and medium socio-demographic index. The identification of biomarkers and the advent of personalized therapies have transformed the way the disease
is treated and changed the lives and quality of life of CLL patients.
Conclusions: CLL remains a current medical and socioeconomic problem, and the behaviour of patients with CLL remains a challenge for the health
system in the Republic of Moldova. The implementation of cyto-genetic and molecular-biological diagnosis is important for the stratification of patients,
the selection of optimal targeted therapy. CLL comorbidity is an independent indicator of treatment response, predisposes to adverse drug effects and
reduces the quality of life of CLL patients. The individual approach to the patient with CLL, the administration of therapy according to international
guidelines will give patients better chances of survival and a longer plateau of stabilization.
